BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 21911310)

  • 1. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma.
    Cho YA; Yoon HJ; Lee JI; Hong SP; Hong SD
    Oral Oncol; 2011 Dec; 47(12):1148-53. PubMed ID: 21911310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
    Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4
    Mattox AK; Lee J; Westra WH; Pierce RH; Ghossein R; Faquin WC; Diefenbach TJ; Morris LG; Lin DT; Wirth LJ; Lefranc-Torres A; Ishida E; Chakravarty PD; Johnson L; Zeng YC; Chen H; Poznansky MC; Iyengar NM; Pai SI
    Cancer Res; 2017 Nov; 77(22):6365-6374. PubMed ID: 28947422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
    Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
    Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer.
    Teng F; Meng X; Kong L; Mu D; Zhu H; Liu S; Zhang J; Yu J
    Transl Res; 2015 Dec; 166(6):721-732.e1. PubMed ID: 26209749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma.
    Kogashiwa Y; Yasuda M; Sakurai H; Nakahira M; Sano Y; Gonda K; Ikeda T; Inoue H; Kuba K; Oba S; Ishikawa J; Enoki Y; Matsumura S; Minami K; Ebihara Y; Sugasawa M
    Anticancer Res; 2017 Mar; 37(3):1417-1424. PubMed ID: 28314313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study.
    Troeltzsch M; Woodlock T; Pianka A; Otto S; Troeltzsch M; Ehrenfeld M; Knösel T
    J Oral Maxillofac Surg; 2017 May; 75(5):969-977. PubMed ID: 27916470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
    Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A
    Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
    Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
    Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G
    Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.
    Droeser RA; Hirt C; Viehl CT; Frey DM; Nebiker C; Huber X; Zlobec I; Eppenberger-Castori S; Tzankov A; Rosso R; Zuber M; Muraro MG; Amicarella F; Cremonesi E; Heberer M; Iezzi G; Lugli A; Terracciano L; Sconocchia G; Oertli D; Spagnoli GC; Tornillo L
    Eur J Cancer; 2013 Jun; 49(9):2233-42. PubMed ID: 23478000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
    Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
    Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.
    Schalper KA; Velcheti V; Carvajal D; Wimberly H; Brown J; Pusztai L; Rimm DL
    Clin Cancer Res; 2014 May; 20(10):2773-82. PubMed ID: 24647569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma.
    Reichert TE; Scheuer C; Day R; Wagner W; Whiteside TL
    Cancer; 2001 Jun; 91(11):2136-47. PubMed ID: 11391595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.
    Baine MK; Turcu G; Zito CR; Adeniran AJ; Camp RL; Chen L; Kluger HM; Jilaveanu LB
    Oncotarget; 2015 Sep; 6(28):24990-5002. PubMed ID: 26317902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
    Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M
    Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uncovering PD-L1 and CD8
    Chen J; Gu P; Wu H
    Biomed Res Int; 2020; 2020():8164365. PubMed ID: 32884946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.